Evidence map›Paper›PMID 28269754›Full record

ArticleCancer biomarkers : section A of Disease markers2017

Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China.

Jingliang Cheng, Shangyi Fu, Chunli Wei, Mousumi Tania, Md Asaduzzaman Khan, Saber Imani, Baixu Zhou, Hanchun Chen, Xiuli Xiao, Jingbo Wu and 1 more

Abstract read
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Aging · 2020
    Article
  5. Article
  6. Detection ofJournal of clinical medicine · 2019
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 4 countries.

Jingliang ChengKey Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, Sichuan 646000, China.
Shangyi FuHonors College, University of Houston, Houston, TX 77204, USA.
Chunli WeiKey Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, Sichuan 646000, China.
Mousumi TaniaKey Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, Sichuan 646000, China.
Md Asaduzzaman KhanKey Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, Sichuan 646000, China.
Saber ImaniKey Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, Sichuan 646000, China.
Baixu ZhouKey Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, Sichuan 646000, China.
Hanchun ChenDepartment of Biochemistry, School of Life Sciencesand the State Key Laboratory of Medical Genetics, Central South University, Changsha, Hunan 410013, China.
Xiuli XiaoDepartment of Pathology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China.
Jingbo WuDepartment of Oncology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China.
Junjiang FuKey Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, Sichuan 646000, China.
Southwest Medical University · CNAffiliated Hospital of Southwest Medical University · CNCentral South University · CNMacau University of Science and Technology · MOUniversity of Houston · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPIK3CA gene encodes the p110 α catalytic subunit of the oncoprotein phosphatidylinositol 3-kinase (PI3 K) which regulates many biological processes such as cell proliferation, differentiation, migration and survival through the activation of various signaling pathways.

objectiveIn this study, we have investigated the possible somatic mutations in PIK3CA gene in invasive ductal breast carcinomas of Chinese women from Western China.

methodsGenomic DNA was extracted from the formalin-fixed paraffin-embedded (FFPE) tissue samples. The hotspot mutations in PIK3CA gene of exon 9 and exon 20 were studied by pyrosequencing.

resultsThe sequencing identified two hotspot mutations in exon 20 of one cancer samples at p. H1047L (c. 3140A > T) and eight cancer sample at p. H1047R (c. 3140A > G). No mutation in exon 9 of PIK3CA gene was found in these breast cancer tissue samples. PIK3CA mutations showed surprising clinicopathological features in breast cancer patients, as incidence of lymph node invasiveness is increased in the patients with PIK3CA mutation. In addition, all the patients showed tumor size bigger than 3 cm in diameter. It is important that for early detection and early treatment for BC in developing countries or areas like Western China, and for people to provide popularization education using scientific knowledge in cancer fields.

conclusionsThis study identified PIK3CA mutations in breast carcinoma patients of Western China that will enable a more rapid molecular diagnosis, and provide a stronger rationale evidence for development of precision therapeutic approaches as well as promising therapeutic targets for breast cancer treatment or patient management.

Indexed as

Pathology, MolecularAdultBiomarkers, TumorBreast NeoplasmsChinaClass I Phosphatidylinositol 3-KinasesExonsFemaleHumansMiddle AgedMutationParaffin EmbeddingSignal TransductionBiomarkers, TumorClass I Phosphatidylinositol 3-KinasesPIK3CA protein, humanBreast cancerDNA mutationphosphatidylinositol 3-kinasePIK3CA genepyrosequencingWestern China

Identifiers

PMID28269754
PMCPMC13020705
OpenAlexW2592658347

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.